In this episode, Joe Moore interviews Christopher Koddermann: Co-Founder and Chair of the Board of Directors of the International Therapeutic Psilocybin Rescheduling Initiative (ITPRI), a group pursuing the rescheduling of psilocybin under the 1971 Convention on Psychotropic Substances – which has made attempts at academic research and clinical trials very time-consuming, overly complicated, and expensive. He discusses patents, IP, and “Psychedelics 2.0,” where companies are patenting new molecules, using IP to create investment interest, and patent-hopping. He also talks about market exclusivity and patents; ketamine, esketamine, and the case of China attempting to schedule ketamine; Ken Kesey; consumer preferences around natural products vs. synthetic; and the entourage effect and baeocystin, a compound present in many mushrooms.

The post PT347 – Christopher Koddermann – Rescheduling Psilocybin, Patents and IP, and The Entourage Effect appeared first on Psychedelics Today.

Previous articleHealth Canada Grants MDMA Production and Distribution Amendment to Optimi Health
Next articleReunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022